作者:Artjom Wischnjow、Dikran Sarko、Maria Janzer、Christina Kaufman、Barbro Beijer、Sebastian Brings、Uwe Haberkorn、Gregor Larbig、Armin Kübelbeck、Walter Mier
DOI:10.1021/acs.bioconjchem.6b00057
日期:2016.4.20
Kidney-specific drug targeting is an attractive strategy to reduce unwanted side effects and to enhance drug efficacy within the renal tissue. For this purpose a novel kidney-specific drug carrier was developed. The peptide sequence (KKEEE)3K triggers exceptional renal specificity at high accumulation rates. Micro-PET imaging studies of megalin-deficient mice indicate that the cellular endocytosis of this carrier is mediated by megalin. This assumption is supported by immunohistochemical analysis of FITC-labeled carrier peptide, which exclusively accumulated at the apical side of proximal tubule cells within the renal cortex. Scintigraphic studies of modified ciprofloxacin conjugated to (KKEEE)3K confirmed the excellent drug targeting potential of the peptide carrier. The conjugate accumulated entirely in the kidneys, revealing flawless redirection of ciprofloxacin, a compound that is mainly excreted by the liver. In conclusion, these results suggest the potential of (KKEEE)3K as a promising candidate for kidney-targeted drug delivery to proximal tubule cells.
肾脏特异性药物靶向是一种有吸引力的策略,可以减轻不必要的副作用并增强药物在肾组织中的疗效。为此,开发了一种新型的肾脏特异性药物载体。肽序列(KKEEE)3K在高积累率下触发了卓越的肾脏特异性。对缺乏巨噬细胞受体(megalin)的小鼠进行的微PET成像研究表明,该载体的细胞内吞作用是由巨噬细胞受体介导的。这一假设得到了FITC标记的载体肽的免疫组化分析的支持,该肽仅在肾皮质中近端小管细胞的顶侧积累。改造的氟喹诺酮与(KKEEE)3K的结合体的闪烁成像研究证实了该肽载体卓越的药物靶向潜力。结合体完全在肾脏中积累,显示了氟喹诺酮的完美重定向,而该化合物主要通过肝脏排泄。总之,这些结果表明(KKEEE)3K作为一种有前景的候选者,具有针对近端小管细胞的肾脏靶向药物递送的潜力。